In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and ...

Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and i ...

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...

Two years after surgery, three patients experienced improved corneal transparency with no serious side effects.

Fate Therapeutics Inc ( (FATE) ) has released its Q3 earnings. Here is a breakdown of the information Fate Therapeutics Inc presented to its ...

The best free logo maker delivers a creative space for designing a logo that helps your business stand out. I've been using online design apps for over ten years, and these are my top ...

The best logo maker is essential for branding your business and standing out online. My team and I have tested the top tools for beginners and professional designers, and everyone in between.

Analysis By Type, By Stem Cell Source, By Application, By End User, By Region Size and Trends Forecast up to 2029" report has ...

d iT, and aß iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...